http://www.osip.com/Researches and develops diagnostics and anticancer therapy in humans and other diseases associated with control of cell growth. Laboratories in Oxford, Boulder and Farmingdale, headquartered in Melville, New York. (Nasdaq: OSIP)Cancer > Research and DevelopmentOSI Pharmaceuticals is committed to "shaping medicine and changing lives" by discovering, developing and commercializing high-quality, novel and differentiated personalized medicines designed to extend life and improve the quality of life for patients with cancer and diabetes/obesity.
Tarceva ® (erlotinib) tablets
Now FDA-approved as maintenance therapy for NSCLC
Tarceva monotherapy is indicated as maintenance treatment in patients with locally advanced or metastatic NSCLC who disease has not progressed after four cycles of platinum-based first-line chemotherapy.
Tarceva isoncologymonotherapydiabetesoncology researchTarcevaEMTEpithelial Mesenchymal TransitionTranslational Research
Develops drugs which block intracellular signal transduction pathways for treating solid tumors and hematologic malignancies. Includes kits available, technology overview and investor data from Cambridge, Massachusetts. (Nasdaq: ARIA)
Details of projects using resistance related to polyunsaturated fatty acids and catalase in vitro, applied in vivo to trout model. Includes publications, charity status, facilities and contacts in Olympia, Washington.
Joining mailing list will entitle you
to receive occasional emails informing you of news and
updates to the site and any special offers that may be
of interest to you.